Directors Dealings
Director dealings are proprietary transactions by executives, which are reportable under Art. 19 MAR. The publication of these transactions is an important contribution to the prevention of insider dealing and market manipulation. In addition, knowledge of such transactions is of great importance to the market, as these transactions provide indications of management's assessment of the company's future business prospects. The information presented here relates to companies that are under the supervision of BaFin.
SCHOTT Pharma AG & Co. KGaA: A reportable insider transaction was published on 4th March 2024. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 4th March 2024,
The Insider Transaction was made by Schulte, Dr. Jens 
. The transaction toke place on 1st March 2024. The order was executed at the trading place Xetra. . The aggregated volume was 80.000,00 EUR, based on an average price of 40,00 EUR. The nature of the Investment was Sell.
SCHOTT Pharma AG & Co. KGaA: A reportable insider transaction was published on 5th October 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 5th October 2023,
The Insider Transaction was made by Wienand, Dr. Wolfgang . The transaction toke place on 2nd October 2023. . The aggregated volume was 47.358,00 EUR, based on an average price of 27,00 EUR. The nature of the Investment was Buy.
SCHOTT Pharma AG & Co. KGaA: A reportable insider transaction was published on 5th October 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 5th October 2023,
The Insider Transaction was made by Goldschmidt, Peter . The transaction toke place on 2nd October 2023. . The aggregated volume was 50.004,00 EUR, based on an average price of 27,00 EUR. The nature of the Investment was Buy.
SCHOTT Pharma AG & Co. KGaA: A reportable insider transaction was published on 5th October 2023. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 5th October 2023,
The Insider Transaction was made by Reisse, Andreas . The transaction toke place on 2nd October 2023. . The aggregated volume was 94.743,00 EUR, based on an average price of 27,00 EUR. The nature of the Investment was Buy.
SCHOTT Pharma AG & Co. KGaA: A reportable insider transaction was published on 5th October 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 5th October 2023,
The Insider Transaction was made by Schulte, Dr. Jens . The transaction toke place on 2nd October 2023. . The aggregated volume was 94.743,00 EUR, based on an average price of 27,00 EUR. The nature of the Investment was Buy.
SCHOTT Pharma AG & Co. KGaA: A reportable insider transaction was published on 5th October 2023. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 5th October 2023,
The Insider Transaction was made by Steinkühler, Dr. Almuth . The transaction toke place on 2nd October 2023. . The aggregated volume was 50.004,00 EUR, based on an average price of 27,00 EUR. The nature of the Investment was Buy.
SCHOTT Pharma AG & Co. KGaA: A reportable insider transaction was published on 5th October 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 5th October 2023,
The Insider Transaction was made by Erkens, Ann-Kristin . The transaction toke place on 2nd October 2023. . The aggregated volume was 47.385,00 EUR, based on an average price of 27,00 EUR. The nature of the Investment was Buy.
| Type | Total | Last | Made by | Go to |
|---|---|---|---|---|
| Equity Story | 16 | 26th September 2024 | EQS Group AG | EQS |
| Corporate Research | 0 | - | - | Corporate Research |
| Short Seller (DE) | 1 | 27th August 2024 | Millennium International Management LP | SSR (DE) |
| Short Seller (UK) | 0 | - | - | SSR (UK) |
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.